Efficacy and safety of sofosbuvir-based therapies in patients with advanced liver disease in a real-life cohort

Código QR

Efficacy and safety of sofosbuvir-based therapies in patients with advanced liver disease in a real-life cohort

Blaise K Kutala,1,2 Feryel Mouri,1 Corinne Castelnau,1 Valerie Bouton,1 Nathalie Giuily,1 Nathalie Boyer,1 Tarik Asselah,1,2 Patrick Marcellin1,2 1Service d’hépatologie, Hopital Beaujon-APHP, 2INSERM – University of Paris Diderot, Paris, France Background: The combinat...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kutala BK, Mouri F, Castelnau C, Bouton V, Giuily N, Boyer N, Asselah T, Marcellin P
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	Sofosbuvir hepatitis C virus interferon-free therapies cirrhosis advanced fibrosis Diseases of the digestive system. Gastroenterology RC799-869
Acceso en línea:	https://doaj.org/article/845b388a5b6148f2a06ca2a277d9ddee
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life
por: Pol S, et al.
Publicado: (2016)

“Let my liver rather heat with wine” - a review of hepatic fibrosis pathophysiology and emerging therapeutics
por: Moscoso CG, et al.
Publicado: (2019)

Cognitive impairment after liver transplantation: residual hepatic encephalopathy or posttransplant encephalopathy?
por: Kornerup LS, et al.
Publicado: (2019)

Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives
por: Degasperi E, et al.
Publicado: (2014)

Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection
por: Sundaram V, et al.
Publicado: (2016)

The pathophysiology of thrombocytopenia in chronic liver disease
por: Mitchell O, et al.
Publicado: (2016)

Universal Index for Cirrhosis (UIC index): The development and validation of a novel index to predict advanced liver disease
por: Ahmed Z, et al.
Publicado: (2018)

Decreasing racial disparity with the combination of ledipasvir–sofosbuvir for the treatment of chronic hepatitis C
por: Naylor PH, et al.
Publicado: (2017)

Identifying High-Risk NASH Patients: What We Know so Far
por: Schulz M, et al.
Publicado: (2020)

A Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis
por: Ganguli S, et al.
Publicado: (2019)

Diagnosis and staging of fibrosis in patients with chronic hepatitis C: comparison and critical overview of current strategies
por: Mendes LC, et al.
Publicado: (2018)

Prospective Comparison of Transient Elastography Using Two Different Devices: Performance of FibroScan and FibroTouch
por: Serra JT, et al.
Publicado: (2020)

Safety and Efficacy of Sofosbuvir and Daclatasvir in The Treatment of Chronic HCV Infection in Elderly Egyptian Patients
por: Mohamed G. Mohamed, et al.
Publicado: (2021)

Perioperative Evolution of Sodium Levels in Cirrhotic Patients Undergoing Liver Transplantation: An Observational Cohort and Literature Review
por: Zamberg I, et al.
Publicado: (2021)

Portosystemic shunts and refractory hepatic encephalopathy: patient selection and current options
por: Philips CA, et al.
Publicado: (2019)

Biomarkers of extracellular matrix formation are associated with acute-on-chronic liver failure
por: Annarein J.C. Kerbert, et al.
Publicado: (2021)

Copeptin as a novel marker predicting prognosis of liver cirrhosis and its major complications
por: Tawfik AK, et al.
Publicado: (2018)

Interrelationship of hepatitis C virus genotypes with patient characteristics in Bahrain
por: Abdulla MA, et al.
Publicado: (2017)

Risk of severe COVID-19 and mortality in patients with established chronic liver disease: a nationwide matched cohort study
por: Tracey G. Simon, et al.
Publicado: (2021)

Effectiveness and safety of two-step percutaneous transhepatic choledochoscopic lithotomy in treatment of complex hepatolithiasis
por: DUAN Changhu
Publicado: (2021)

p70 Ribosomal Protein S6 Kinase Is a Checkpoint of Human Hepatic Stellate Cell Activation and Liver Fibrosis in MiceSummary
por: Florian P. Reiter, et al.
Publicado: (2022)

Adjunct Fenofibrate Up‐regulates Bile Acid Glucuronidation and Improves Treatment Response For Patients With Cholestasis
por: Gina M. Gallucci, et al.
Publicado: (2021)

Tyrosine levels are associated with insulin resistance in patients with nonalcoholic fatty liver disease
por: Kawanaka M, et al.
Publicado: (2015)

Update on blood‐based biomarkers for chronic liver diseases prognosis: Literature review and institutional experience
por: Motoh Iwasa, et al.
Publicado: (2021)

Approaches to the Diagnosis of Portal Hypertension: Non-Invasive or Invasive Tests?
por: Dajti E, et al.
Publicado: (2021)

Weekly cisplatin may reverse liver dysfunction and jaundice caused by diffuse liver metastases of solid tumors
por: M Gabrovska, et al.
Publicado: (2009)

Associations Between Alcohol Use and Liver‐Related Outcomes in a Large National Cohort of Patients With Cirrhosis
por: Meredith M. Pearson, et al.
Publicado: (2021)

Epidemiology of drug-induced liver injury
por: LI Xiaoyun
Publicado: (2021)

Autonomic dysfunction in chronic liver disease
por: Frith J, et al.
Publicado: (2011)

Association between liver fibrosis progression and endothelin-1/nitric oxide in patients with nonalcoholic fatty liver disease
por: LI Pinhua
Publicado: (2021)

GLP-1 Receptor Agonist Effects on Lipid and Liver Profiles in Patients with Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis
por: Shahla Rezaei, et al.
Publicado: (2021)

Clinical manifestations and typing of drug-induced liver injury
por: YANG Wanna
Publicado: (2021)

Drug-induced liver injury: Advances and confusions in treatment
por: CHEN Shuai
Publicado: (2021)

Challenging hepatitis C-infected liver transplant patients
por: Oliver M, et al.
Publicado: (2016)

Pathological features and pathological diagnosis of drug-induced liver injury
por: YANG Yongfeng
Publicado: (2021)

Evolving concepts in the selection of immunosuppression regimen for liver transplant recipients
por: Locke JE, et al.
Publicado: (2011)

Lifestyle interventions for the treatment of non-alcoholic fatty liver disease
por: Bradford V, et al.
Publicado: (2013)

A Predictive Model for Avoiding Follow-Up Paracentesis in Spontaneous Bacterial Peritonitis
por: Ana Luísa Santos, et al.
Publicado: (2021)

Pathogenesis of drug-induced liver injury: Current understanding and future needs
por: YU Yuecheng
Publicado: (2021)

Surgical treatment of nonalcoholic fatty liver disease in severely obese patients
por: Vander Naalt SJ, et al.
Publicado: (2014)